Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,279.20
(
-1.78%
)
Dow Jones
49,526.11
(
-1.07%
)
Brent Oil
106.70
(
2.42%
)
Bitcoin
79,080.92
(
-2.44%
)
News Focus
News Focus
Post# of 257577
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122987
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: oc631 post# 163194

Saturday, 06/29/2013 1:08:02 PM

Saturday, June 29, 2013 1:08:02 PM

Post# of 257577

GILD/ABBV/ENTA/Medivir/etc—Seeing 90+% SVR rates with the first-generation oral combo from GILD brings into question the long-term utility of the P.I. class.

Respectfully disagree. GILD hasn’t yet produced an oral GT1 regimen that’s even close to being competitive with the 93% SVR rate in null responders observed in ABBV’s AVIATOR study (#msg-80736847).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today